Search research articles
Contact Us
Filters
Showing results (61-70 of 242) with videos related to
Page
of 25
Sort By:
The Oncologist
|
April 19, 2002
The molecular perspective: tamoxifen and the estrogen receptor
David S Goodsell
Stem Cells (Dayton, Ohio)
|
October 20, 1999
The molecular perspective: methotrexate
D S Goodsell
The Oncologist
|
January 13, 2000
The molecular perspective: matrix metalloproteinase 2
D S Goodsell
The Oncologist
|
September 7, 1999
The molecular perspective: methotrexate
D S Goodsell
The Oncologist
|
May 5, 2000
The molecular perspective: cyclooxygenase-2
D S Goodsell
Stem Cells (Dayton, Ohio)
|
February 8, 2000
The molecular perspective: matrix metalloproteinase 2
D S Goodsell
The Oncologist
|
October 21, 2000
The molecular perspective: caspases
D S Goodsell
Stem Cells (Dayton, Ohio)
|
November 29, 2002
The molecular perspective: cadherin
David S Goodsell
Stem Cells (Dayton, Ohio)
|
January 17, 2003
The molecular perspective: VEGF and angiogenesis
David S Goodsell
The Oncologist
|
February 13, 2001
The molecular perspective: targeted toxins
D S Goodsell
Page
of 25
Search research articles
Search
Showing results (61-70 of 242) with videos related to
Sort By:
Page
of 25
The Oncologist
|
April 19, 2002
The molecular perspective: tamoxifen and the estrogen receptor
David S Goodsell
Stem Cells (Dayton, Ohio)
|
October 20, 1999
The molecular perspective: methotrexate
D S Goodsell
The Oncologist
|
January 13, 2000
The molecular perspective: matrix metalloproteinase 2
D S Goodsell
The Oncologist
|
September 7, 1999
The molecular perspective: methotrexate
D S Goodsell
The Oncologist
|
May 5, 2000
The molecular perspective: cyclooxygenase-2
D S Goodsell
Stem Cells (Dayton, Ohio)
|
February 8, 2000
The molecular perspective: matrix metalloproteinase 2
D S Goodsell
The Oncologist
|
October 21, 2000
The molecular perspective: caspases
D S Goodsell
Stem Cells (Dayton, Ohio)
|
November 29, 2002
The molecular perspective: cadherin
David S Goodsell
Stem Cells (Dayton, Ohio)
|
January 17, 2003
The molecular perspective: VEGF and angiogenesis
David S Goodsell
The Oncologist
|
February 13, 2001
The molecular perspective: targeted toxins
D S Goodsell
Page
of 25